Aurobindo Pharma (AUROPHARMA) investor relations material

Executive summary

• Achieved record revenues and EBITDA margins for both Q4 and FY 2026, with strong growth across core businesses and geographies; Q4FY26 revenue reached ₹8,853 crore, up 5.6% year-over-year, driven by Europe growth and stable US performance.

• Audited standalone and consolidated financial results for the year and quarter ended March 31, 2026, were approved with unmodified opinions from statutory auditors.

• Diversified product portfolio and strategic initiatives in biosimilars, CDMO, and backward integration underpin long-term growth.

• Board approved buyback of 5,423,728 equity shares for ₹8,000 million, completed in May 2026.

• Several new subsidiaries were incorporated and a business acquisition was completed during the year.

Financial highlights

• FY 2026 consolidated revenue reached ₹336,530.8 million, up from ₹317,237.3 million in FY25; Q4 revenue was ₹8,853 crore, up 5.6% YoY.

• EBITDA for Q4FY26 was ₹1,801 crore with a margin of 20.3%; FY26 EBITDA at ₹6,856 crore, margin 20.4%.

• Net profit for Q4 grew 2% YoY to ₹921 crore; consolidated net profit after tax for FY26 was ₹35,029.7 million.

• Gross margin for Q4 at 61.3%, up 216 bps YoY; R&D spend for FY26 was ₹1,590 crore (5% of revenue).

• Net cash position improved to ₹317 million at March 2026 after acquisition payments; free cash flow and positive net cash position maintained.

Outlook and guidance

• FY 2027 expected to see sustained and improving EBITDA margins, targeting above 21%.

• U.S. business aims for $2 billion revenue in 1–2 years, contingent on acquisitions and new launches.

• Europe business targets double-digit constant currency growth, with continued momentum from China supplies.

• Continued focus on biosimilars and specialty products, with significant R&D investment and expansion of biosimilars pipeline and manufacturing capacity.

• The acquisition of Lannett Company LLC is pending regulatory approval, with no financial impact yet.